CagriSema

An investigational combination of cagrilintide and semaglutide that targets both amylin and GLP-1 pathways, producing greater weight loss than either medication alone.

SGLT2 Inhibitors and Weight

Diabetes medications that promote weight loss by causing the kidneys to excrete excess sugar in urine, resulting in a modest caloric deficit and cardiovascular protection.

Tesofensine

An investigational triple reuptake inhibitor that suppresses appetite by increasing serotonin, noradrenaline, and dopamine in the brain.

Amylin Analogues

Medications that mimic the natural hormone amylin to slow digestion, reduce appetite, and support weight management.

Survodutide

A dual GLP-1/glucagon receptor agonist with potential benefits for both weight loss and liver health.

Mazdutide

An investigational GLP-1/glucagon dual agonist showing promising weight loss in clinical trials.

Retatrutide

An investigational triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss results in clinical trials.

Setmelanotide

Setmelanotide (Imcivree) is an injectable medication targeting a brain pathway controlling hunger, approved for rare genetic forms of obesity.

Cagrilintide

Cagrilintide is a long-acting amylin analogue that enhances satiety, being studied in combination with semaglutide for powerful weight loss.

Dulaglutide (Trulicity)

Dulaglutide (Trulicity) is a once-weekly GLP-1 injection that helps control blood sugar and supports weight loss by reducing appetite and slowing digestion.